APP inhibitors(Beta amyloid A4 protein inhibitors), TAU inhibitors(Microtubule-associated protein tau inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseCardiovascular Diseases+ [1]

Active Indication

Alzheimer DiseaseParkinson DiseaseLewy Body Disease+ [2]

Inactive Indication

Mild cognitive disorderYoung onset Parkinson disease

Originator Organization

National Institute on Aging

Active Organization

Annovis Bio, Inc.

Inactive Organization-

License Organization

National Institute on Aging

Annovis Bio, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC20H23N3O2

InChIKeyPBHFNBQPZCRWQP-AZUAARDMSA-N

CAS Registry116839-68-0

Clinical Trials associated with Buntanetap

NCT07284784

/ RecruitingPhase 2/3

An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Start Date09 Jan 2026

Sponsor / Collaborator

Annovis Bio, Inc.

[+1]

NCT06709014

/ Active, not recruitingPhase 3

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
* Take buntanetap/Posiphen or a placebo every day for 18 months
* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
* Complete pre- and post-clinic visit phone calls

Start Date04 Feb 2025

Sponsor / Collaborator

Annovis Bio, Inc.

[+2]

NCT05686044

/ CompletedPhase 2/3

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease

The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.
Study details include:
The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home.
The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.

Start Date01 Apr 2023

Sponsor / Collaborator

Annovis Bio, Inc.

100 Clinical Results associated with Buntanetap

100 Translational Medicine associated with Buntanetap

100 Patents (Medical) associated with Buntanetap

Literatures (Medical) associated with Buntanetap

01 May 2026·BIOCHEMISTRY-MOSCOW

A Conjugate of Aminoadamantane and Tetrahydro-γ-Carboline Inhibits Accumulation of Mutant α-Synuclein A53T in the Cellular Model of Proteinopathy

Article

Author: Bachurin, Sergei O ; Kukharsky, Michail S ; Fisenko, Vladimir P ; Kukharskaya, Olga A ; Pukaeva, Nadezhda E ; Pukhov, Sergey A ; Kryshkova, Victoria S ; Stavrovskaya, Alla V ; Nazdracheva, Maya R ; Burak, Marina V ; Rachenkov, Kirill A

Pathological aggregation of α-synuclein is a key event in the development of synucleinopathies, such as Parkinson's disease and Lewy body dementia. Currently, no effective disease-modifying therapy is available, necessitating the search for new therapeutic agents. One promising strategy involves the use of low-molecular-weight compounds capable of inhibiting the formation of toxic protein aggregates. This study evaluates the anti-aggregation properties of EC3222x, a conjugate of pharmacophoric fragments of amantadine and a fluorinated derivative of tetrahydro-γ-carboline. α-Synucleinopathy was modeled in the SH-SY5Y neuroblastoma cell line by transfection with a plasmid vector encoding the mutant human α-synuclein A53T protein. EC3222x at a concentration of 1 µM reduced the number of cells with α-synuclein A53T aggregates. Its efficacy was comparable to that of SynuClean-D and Buntanetap, known inhibitors of α-synuclein aggregation. Treatment with EC3222x reduced both the level of diffusely distributed intracellular α-synuclein and the formation of mature fibrillar aggregates and large aggresomes. Importantly, EC3222x did not affect the accumulation of another aggregation-prone protein, TDP-43, in a similar cellular model, indicating its specificity for α-synuclein. These findings suggest that EC3222x may represent a promising candidate for the development of therapeutic agents targeting synucleinopathies.

01 Dec 2025·Alzheimers & Dementia

Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases

Article

Author: Maccecchini, Maria L. ; Fang, Cheng ; Morin, Alexander ; Peterson, Matthew J

Abstract:

Background:

Buntanetap (formerly Posiphen) is an orally bioavailable small molecule that improves cognitive function in patients with early Alzheimer’s (AD) and Parkinson’s (PD) diseases. Buntanetap is lipophilic and has high blood‐brain barrier penetrability and brain uptake (10:1 brain:plasma ratio). In SAD and MAD studies, at all doses, buntanetap showed similar profiles, it was absorbed rapidly and cleared from the circulation bi‐phasically, independent of dose. This analysis aims to further evaluate the pharmacokinetics (PK) of buntanetap in AD and PD populations.

Method:

The following parameters were measured across two RCTs for buntanetap doses ranging between 7.5mg‐30mg: C max , T max , AUC 0‐t , AUC 0‐∞ , t 1/2 . In AD (NCT05686044, Phase II/III, N=351), PK samples were obtained at 0h and then 1h, 2h, and 4h after drug administration (0, 7.5mg, 15 mg, 30mg QD). In PD (NCT05357989, Phase III, N=523), two cohorts of PK samples were obtained: sparse and dense (0, 10 mg, 20mg QD). In the sparse group, PK samples were obtained at 0h and then 1.5h after drug administration. In the dense group, PK samples were obtained at 0h and then 1h, 1.5h, and 2h‐10h (hourly) after drug administration.

Result:

Calculated PK parameters for buntanetap in plasma for AD (Table 1) and PD patients (Table 2) had many similarities. C max and AUC 0‐t for AD and PD (dense) increased at the same rate in a dose‐proportional manner; PD (sparse) increased with dose as well, but its response was more muted overall. Mean T max ranged from 1.34‐1.88h across all doses in both AD and PD patients. Mean t 1/2 was comparable and ranged from 1.55‐1.74h in AD and 2.01‐2.57h in PD. The 30mg dose in AD did not follow the increasing trend for AUC 0‐∞ as in the lower doses for AD and PD (dense), which was likely underpowered by the sampling of this measure ( N =2).

Conclusion:

Analyses from two RCTs confirmed similar mean C max , T max , and AUC 0‐t across doses of 7.5mg‐30mg buntanetap in both patients with early AD and PD. These data confirm fast plasma peak, as seen in all of our previous studies, and dose‐dependent exposure to drug, supporting buntanetap’s PK uniformity across AD and PD indications.

01 Dec 2025·Alzheimers & Dementia

Advancing Buntanetap: Comparative Pharmacokinetic Characterization of the Original Semi‐Crystalline with the Novel Crystalline Form in Animals and Humans

Article

Author: Christie, Michael ; Maccecchini, Maria L. ; Morin, Alexander

Abstract:

Background:

Buntanetap is an orally bioavailable small molecule that improves cognitive function in patients with early Alzheimer’s and Parkinson’s diseases. Until now, a semi‐crystalline anhydrate (Form A) has been used in preclinical and clinical studies. However, recently a novel crystal dihydrate buntanetap (Form B) was discovered, offering improved solid‐state stability without compromising its bioavailability, metabolism and treatment efficacy. We present the pharmacokinetic (PK) profile of Forms A and B from bridge studies conducted in mice, dogs, and humans.

Method:

Form B was identified during a polymorph screen and structurally characterized by X‐Ray Powder Diffraction (XRPD). CD‐1 mice ( n =6) received 50mg/kg buntanetap via oral gavage; plasma, CSF, and brain samples were collected at intervals up to 10h. Beagle dogs ( n =12) were dosed orally with 20mg/kg, with plasma collected up to 12h post‐dose. Human volunteers ( n =35) received a 50mg buntanetap capsule, and plasma was sampled up to 24h. Buntanetap levels were assessed by LC‐MS/MS and non‐compartmental analysis.

Result:

The two forms are distinct, do not interconvert, and exhibit comparable PK profiles across species. Forms A and B reach fast plasma Cmax (<2h), high brain/CSF and brain/plasma ratios, and complete systemic clearance by 12h post‐dose. Furthermore, both forms produce identical PK patterns for its primary metabolites, N1‐ and N8‐norbuntanetap, confirming that Form B retains the established metabolic characteristics of buntanetap.

Conclusion:

These findings support the continued development of Form B for future clinical use, as it combines enhanced solid‐state stability with a preserved PK profile essential for buntanetap’s therapeutic efficacy. Form B has also been approved by the FDA for all future clinical studies including the ongoing pivotal Phase 3 Early AD trial.

144

News (Medical) associated with Buntanetap

26 May 2026

·www.biospace.com

Annovis Bio Regains NYSE Listing Compliance

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards. On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equity was also below $50 million. On June 19, 2025, the NYSE accepted the Company's plan to regain compliance and granted an 18-month cure period from the date of the original notice. To address it, Annovis executed a series of corrective actions to restore its market capitalization and stockholders' equity above the required thresholds and provided the NYSE with quarterly progress updates as required under the plan. Following these measures, the NYSE has confirmed that Annovis has regained full compliance with all applicable continued listing requirements. The Company's common stock will continue to be listed and traded on the NYSE under the ticker symbol "ANVS." "We are pleased to have regained full NYSE compliance in just 12 months, well ahead of the 18-month deadline, and we thank the NYSE for their engagement throughout this process," said Alexander Morin, Ph.D., Director, Strategic Communications. "With this matter behind us, our attention remains firmly on advancing our clinical programs toward key milestones, with topline data readout from the pivotal Phase 3 AD study and the regulatory submissions on the horizon." About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn , YouTube , and X . Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at . Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

Phase 3

20 May 2026

·www.biospace.com

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of issuance. All of the shares of common stock and the accompanying warrants are being offered by Annovis. The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering. Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $15.0 million, excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions. Canaccord Genuity is acting as the sole bookrunner in the offering. Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in clinical studies for Alzheimer’s disease (AD) and Parkinson’s Disease (PD) and for working capital and general corporate purposes. The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com . Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction. About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn , YouTube , and X . Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

20 May 2026

·www.biospace.com

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canaccord Genuity is acting as the sole bookrunner in the offering. Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease (AD), and for working capital and general corporate purposes. The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com . Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction. About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit and follow us on LinkedIn, YouTube, and X. Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com

100 Deals associated with Buntanetap

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15317

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Annovis Bio, Inc.	04 Feb 2025
Parkinson Disease	Phase 3	United States	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Germany	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Hungary	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Italy	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Poland	Annovis Bio, Inc.	03 Aug 2022
Parkinson Disease	Phase 3	Spain	Annovis Bio, Inc.	03 Aug 2022
Young onset Parkinson disease	Phase 2	United States	Annovis Bio, Inc.	14 Aug 2020
Lewy Body Disease	Phase 2	-	Annovis Bio, Inc.	-
Mild cognitive disorder	Phase 1	United States	Annovis Bio, Inc.	01 Feb 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05686044 (CTgov)	Phase 2/3	Alzheimer Disease	351	Placebo (Placebo)	tnggtjmxgj(ugfgsszkpv) = vhfuqqxwui mryvymbjiq (oriasgymka, 0.533) View more	-	29 Apr 2025
				Buntanetap/Posiphen (7.5mg Buntanetap/Posiphen)	tnggtjmxgj(ugfgsszkpv) = akrberwsnv mryvymbjiq (oriasgymka, 0.526) View more
NCT05357989 (CTgov)	Phase 3	Parkinson Disease	523	Placebo (Placebo)	tudirvinyw(xefudmuuhp) = rqbdqazodg ylpzlwuyle (fdxlrzptyc, 0.311) View more	-	03 Mar 2025
				buntanetap/posiphen (10 mg Buntanetap/Posiphen)	tudirvinyw(xefudmuuhp) = vsmxqacgbn ylpzlwuyle (fdxlrzptyc, 0.312) View more
NCT05357989 (Biospace) Manual	Phase 3	Parkinson Disease	-	Buntanetap	ztljzmdyim(hdqlyxzila) = In patients diagnosed with PD for longer than 3 years (MH>3), with measurable declines in MDS-UPDRS Part II, 20mg buntanetap significantly improved MDS-UPDRS Part II, Part III, Part II+III, and Total scores compared to placebo and baseline thjippozec (kzysalmdvz ) View more	Positive	02 Jul 2024
				Placebo
GlobeNewswire Manual	Not Applicable	Alzheimer Disease	-	Buntanetap 15mg	smihzzqejr(qojvwmvqhq) = utsknjvwhx lfudfbdras (oiwmabzyai )	Positive	11 Jun 2024
				Placebo	smihzzqejr(qojvwmvqhq) = zqwjzlziee lfudfbdras (oiwmabzyai )
NCT05686044 (Biospace) Manual	Phase 2/3	Alzheimer Disease	325	Buntanetap 7.5 mg	grxtrhcmrw(krvqexuhjx) = dgdcrlvpcj gykbnsvyis (cuzjlwvmqx, 0.87)	Positive	29 May 2024
				Buntanetap 15 mg	grxtrhcmrw(krvqexuhjx) = rfmtxuugip gykbnsvyis (cuzjlwvmqx, 0.81)
NCT05686044 (Biospace) Manual	Phase 2/3	Alzheimer Disease	107	Buntanetap	jsprsyaotf(kyispolisy) = enylobrcjy jntihvixff (ylkpyywjhh )	Positive	30 Oct 2023
NCT04524351 (CTgov)	Phase 1/2	Young onset Parkinson disease \| Alzheimer Disease	75	Posiphen (Posiphen, 80mg (Parkinson's Participants))	sucfzsbyto = ggfkkrlhtw hekpvpqrjw (cebjmdhnei, kbtpbaosuw - gpsvuzwhut) View more	-	28 Feb 2023
				Posiphen (Posiphen, 40mg (Parkinson's Participants))	sucfzsbyto = rxpvbnddts hekpvpqrjw (cebjmdhnei, lioxyjnttk - baarsvvdeu) View more
NCT02925650 (CTAD2022)	Phase 1	Mild cognitive disorder CSF Aβ42/40	19	Posiphen	ozdscjfnef(ftnnyfigcm) = 8/19 participants reported headache either during CSF sampling (4),after the procedure (3), or both (1). 5 had blood patches with rapid resolution of headache. hqyshbbqbg (eozenshpiq )	-	03 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis